Orexo’s key market today is the American market for buprenorphine/naloxone products. Orexo operates in the market through the commercialization of Zubsolv®, which is an effective drug for people suffering form opioid addiction. Dying from an overdose is one of the most common causes of deaths in the US and in 2017 more than 70,200 Americans died of an overdose, mainly caused by opioids.1 The problem is classified as an epidemic. Several important federal initiatives have been taken to increase access to treatment, and this creates scope for continued strong growth.

 1 Center of Disease Control